Search

Your search keyword '"Khan, Muhammad Shahzeb"' showing total 706 results
Start Over Author "Khan, Muhammad Shahzeb" Publication Year Range Last 3 years
706 results on '"Khan, Muhammad Shahzeb"'

10. Antero-lateral vs. antero-posterior electrode position for cardioversion of atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials

Author

Asad, Zain Ul Abideen, Imran, Sana, Parmar, Miloni, Bajwa, Awais, Truong, Derek, Agarwal, Siddharth, Ghani, Asad, Clifton, Shari, Reese, Jessica, Khan, Muhammad Shahzeb, Munir, Muhammad Bilal, DeSimone, Christopher V., Sivaram, Chittur, Jackman, Warren M., Po, Sunny, Stavrakis, Stavros, and Al-Khatib, Sana M.

Published
2023
Full Text
View/download PDF

11. The need for increased pragmatism in cardiovascular clinical trials

Author

Usman, Muhammad Shariq, Van Spall, Harriette GC, Greene, Stephen J, Pandey, Ambarish, McGuire, Darren K, Ali, Ziad A, Mentz, Robert J, Fonarow, Gregg C, Spertus, John A, Anker, Stefan D, Butler, Javed, James, Stefan K, and Khan, Muhammad Shahzeb

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Comparative Effectiveness Research, Cardiovascular, Heart Disease, Clinical Trials and Supportive Activities, Prevention, Clinical Research, Good Health and Well Being, Cardiovascular Diseases, Humans, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

The majority of cardiovascular randomized controlled trials (RCTs) test interventions in selected patient populations under explicitly protocol-defined settings. Although these 'explanatory' trial designs optimize conditions to test the efficacy and safety of an intervention, they limit the generalizability of trial findings in broader clinical settings. The concept of 'pragmatism' in RCTs addresses this concern by providing counterbalance to the more idealized situation underpinning explanatory RCTs and optimizing effectiveness over efficacy. The central tenets of pragmatism in RCTs are to test interventions in routine clinical settings, with patients who are representative of broad clinical practice, and to reduce the burden on investigators and participants by minimizing the number of trial visits and the intensity of trial-based testing. Pragmatic evaluation of interventions is particularly important in cardiovascular diseases, where the risk of death among patients has remained fairly stable over the past few decades despite the development of new therapeutic interventions. Pragmatic RCTs can help to reveal the 'real-world' effectiveness of therapeutic interventions and elucidate barriers to their implementation. In this Review, we discuss the attributes of pragmatism in RCT design, conduct and interpretation as well as the general need for increased pragmatism in cardiovascular RCTs. We also summarize current challenges and potential solutions to the implementation of pragmatism in RCTs and highlight selected ongoing and completed cardiovascular RCTs with pragmatic trial designs.

Published
2022

13. Contributors

Author

Alahmad, Waleed, primary, Anjum, Zayeema, additional, Arain, Muhammad Balal, additional, Ashfaq, Alweera, additional, Cetinkaya, Ahmet, additional, Chawala, Varsha, additional, Dar, B.N., additional, Fauzi, Ainil Hawa Mohamad, additional, Halabi, Ahmad, additional, Haq, Hameed Ul, additional, Harshavardhini, R.K., additional, Jananipriya, S., additional, Kaloo, Insha, additional, Kamaruzaman, Sazlinda, additional, Kaya, S. Irem, additional, Khan, Muhammad Jahangir, additional, Khan, Muhammad Shahzeb, additional, Kheto, Ankan, additional, Khursheed, Nazia, additional, Majid, Darakshan, additional, Makroo, Hilal A., additional, Miskam, Mazidatulakmam, additional, Mohamed, Ahmad Husaini, additional, Naqash, Saadiya, additional, Nojavan, Saeed, additional, Ozcelikay-Akyildiz, Goksu, additional, Ozkan, Sibel A., additional, Prakash Maran, J., additional, Radhakrishnan, R., additional, Ronaldo Anuf, A., additional, Salehpour, Niloofar, additional, Sehrawat, Rachna, additional, Sharma, Loveleen, additional, Tabani, Hadi, additional, Varanusupakul, Pakorn, additional, Varanusupakul, Puttaraksa, additional, Wang, Lang, additional, Wu, Long, additional, Yahaya, Nazariyah, additional, Yahaya, Noorfatimah, additional, Yahya, Hafiza, additional, Yahya, Hanis Nadia, additional, Yang, Zhihan, additional, Younis, Kaiser, additional, Yousuf, Owais, additional, Zain, Nur Nadhirah Mohamad, additional, Zhang, Ling, additional, and Zhu, Zhi, additional

Published
2024
Full Text
View/download PDF

16. Environmental impact of nanomaterials

Author

Farhan, Ahmad, primary, Munawar, Junaid, additional, Nawaz, Shahid, additional, Rashid, Ehsan Ullah, additional, Qayyum, Wajeeha, additional, and Khan, Muhammad Shahzeb, additional

Published
2024
Full Text
View/download PDF

17. Electrospun fibers: promising materials for oil water separation

Author

Khan, Muhammad Shahzeb, primary, Asif, Muhammad Ibrar, additional, Karim, Hira, additional, Zainab, Syeda Alvia, additional, Asif, Muhammad, additional, Sohail, Muhammad, additional, Ali, Mohsin, additional, Munawar, Junaid, additional, Nawaz, Shahid, additional, and Haq, Hameed Ul, additional

Published
2024
Full Text
View/download PDF

18. Cardiovascular Safety Reporting in Contemporary Breast Cancer Clinical Trials

Author

Hamid, Arsalan, Anker, Markus S, Ruckdeschel, John C, Khan, Muhammad Shahzeb, Tharwani, Arsal, Oshunbade, Adebamike A, Kipchumba, Rodney K, Thigpen, Samuel C, Anker, Stefan D, Fonarow, Gregg C, Hall, Michael E, and Butler, Javed

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Patient Safety, Cardiovascular, Clinical Trials and Supportive Activities, Cancer, Clinical Research, Heart Disease, Breast Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Breast Neoplasms, Female, Humans, Troponin, cancer therapy, cardio-oncology, cardiovascular disease, pharmacotherapy, safety, cardio‐oncology, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

Background Several cancer therapies have been associated with cardiovascular harm in early-phase clinical trials. However, some cardiovascular harms do not manifest until later-phase trials. To limit interdisease variability, we focused on breast cancer. Thus, we assessed the reporting of cardiovascular safety monitoring and outcomes in phase 2 and 3 contemporary breast cancer clinical trials. Methods and Results We searched Embase and Medline records for phase 2 and 3 breast cancer pharmacotherapy trials. We examined exclusion criterion as a result of cardiovascular conditions, adverse cardiovascular event reporting, and cardiovascular safety assessment through cardiovascular imaging, ECG, troponin, or natriuretic peptides. Fisher's exact test was utilized to compare reporting. Fifty clinical trials were included in our study. Patients were excluded because of cardiovascular conditions in 42 (84%) trials. Heart failure was a frequent exclusion criterion (n=31; 62% trials). Adverse cardiovascular events were reported in 43 (86%) trials. Cardiovascular safety assessments were not reported in 23 (46%) trials, whereas natriuretic peptide and troponin assessments were not reported in any trial. Cardiovascular safety assessments were more frequently reported in industry-funded trials (69.2% versus 0.0%; P

Published
2022

21. Interleukin-6 and Cardiovascular Events in Healthy Adults: MESA

Author

Khan, Muhammad Shahzeb, Talha, Khawaja M., Maqsood, Muhammad Haisum, Rymer, Jennifer A., Borlaug, Barry A., Docherty, Kieran F., Pandey, Ambarish, Kahles, Florian, Cikes, Maja, Lam, Carolyn S.P., Ducharme, Anique, Voors, Adrian A., Hernandez, Adrian F., Lincoff, A. Michael, Petrie, Mark C., Ridker, Paul M., and Fudim, Marat

Published
2024
Full Text
View/download PDF

27. Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure

Author

Usman, Muhammad Shariq, Khan, Muhammad Shahzeb, Fonarow, Gregg C, Greene, Stephen J, Friede, Tim, Vaduganathan, Muthiah, Filippatos, Gerasimos, Coats, Andrew J Stewart, Anker, Stefan D, and Butler, Javed

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cardiovascular, Heart Disease, Good Health and Well Being, Glucose, Heart Failure, Humans, Sodium, Sodium-Glucose Transporter 2 Inhibitors, Symporters, Fragility index, Robustness, Sodium-glucose co-transporter 2 inhibitors, Cardiac failure, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

AimsRecent trials have evaluated sodium-glucose co-transporter 2 inhibitors in patients with heart failure (HF). We sought to assess the robustness of findings from these trials using the fragility index (FI).Methods and resultsFragility index is defined as the minimum number of patients that must be moved from the 'non-event' to the 'event' group to turn a statistically significant result to non-significant. In addition to FI, fragility quotient [(FQ); FI divided by the sample size] was calculated to assess the proportion of events that must be moved to change the significance. For statistically non-significant outcomes, reverse fragility index (RFI) and reverse fragility quotient (RFQ) were calculated. Robustness of findings after pooling data from all three trials was also assessed. A robust reduction in first HF hospitalization or cardiovascular mortality was seen with dapagliflozin (FI = 62 and FQ = 0.013), empagliflozin (FI = 50 and FQ = 0.013), and sotagliflozin (FI = 60 and FQ = 0.049). Dapagliflozin nominally improved all-cause and cardiovascular mortality, with modest FI (n = 8 and 5) and FQ (0.002 and 0.001). Empagliflozin and sotagliflozin did not demonstrate statistically significant reductions in all-cause mortality, with modest RFI (empagliflozin: RFI = 26 and RFQ = 0.007; sotagliflozin: RFI = 6 and RFQ = 0.005). A similar trend was seen with cardiovascular mortality (empagliflozin: RFI = 24 and RFQ = 0.006; sotagliflozin: RFI = 7 and RFQ = 0.006). Upon meta-analysis, the result for first HF hospitalization or cardiovascular mortality was robust (FI = 95 and FQ = 0.010). The reductions in all-cause (FI = 12 and FQ = 0.001) and cardiovascular mortality (FI = 9 and FQ = 0.001), while statistically significant, were fragile.ConclusionImprovement in the composite outcome of first HF hospitalization or cardiovascular death was highly concordant and robust across sodium-glucose co-transporter 2 inhibitor trials. In contrast, secondary endpoints of all-cause and cardiovascular mortality were statistically fragile, underscoring the need to power trials for mortality to fully understand the benefit of therapies on fatal events.

Published
2022

30. Closing the Last Mile Gap in Access to Multimodality Imaging in Rural Settings: Design of the Imaging Core of the Risk Underlying Rural Areas Longitudinal Study

Author

Fazlalizadeh, Hooman, Khan, Muhammad Shahzeb, Fox, Ervin R., Douglas, Pamela S., Adams, David, Blaha, Michael J., Daubert, Melissa A., Dunn, Gary, van den Heuvel, Edwin, Kelsey, Michelle D., Martin, Randolph P., Thomas, James D., Thomas, Yngvil, Judd, Suzanne E., Vasan, Ramachandran S., Budoff, Matthew J., and Bloomfield, Gerald S.

Published
2024
Full Text
View/download PDF

36. Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: A Pooled Cohort Analysis

Author

Patel, Kershaw V., Segar, Matthew W., Klonoff, David C., Khan, Muhammad Shahzeb, Usman, Muhammad Shariq, Lam, Carolyn S.P., Verma, Subodh, DeFilippis, Andrew P., Nasir, Khurram, Bakker, Stephan J.L., Westenbrink, B. Daan, Dullaart, Robin P.F., Butler, Javed, Vaduganathan, Muthiah, and Pandey, Ambarish

Published
2024
Full Text
View/download PDF

39. Association of Chronic Renal Insufficiency with Inhospital Outcomes in Primary Heart Failure Hospitalizations (Insights from the National Inpatient Sample 2004 to 2018)

Author

Minhas, Abdul Mannan Khan, Bhopalwala, Huzefa M., Dewaswala, Nakeya, Ijaz, Sardar Hassan, Khan, Muhammad Shahzeb, Khan, Muhammad Zia, Dani, Sourbha S., Warraich, Haider J., Greene, Stephen J., Edmonston, Daniel L., Lopez, Renato D., Virani, Salim S., Bhopalwala, Adnan, and Fudim, Marat

Published
2023
Full Text
View/download PDF

44. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs

Author

Hussain, Aliza, Ramsey, David, Lee, Michelle, Mahtta, Dhruv, Khan, Muhammad Shahzeb, Nambi, Vijay, Ballantyne, Christie M., Petersen, Laura A., Walker, Adrienne D., Kayani, Waleed T., Butler, Javed, Slipczuk, Leandro, Rogers, Joseph G., Bozkurt, Biykem, Navaneethan, Sankar D., and Virani, Salim S.

Published
2023
Full Text
View/download PDF

49. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations

Author

Usman, Muhammad Shariq, Siddiqi, Tariq Jamal, Anker, Stefan D., Bakris, George L., Bhatt, Deepak L., Filippatos, Gerasimos, Fonarow, Gregg C., Greene, Stephen J., Januzzi, James L., Jr, Khan, Muhammad Shahzeb, Kosiborod, Mikhail N., McGuire, Darren K., Piña, Ileana L., Rosenstock, Julio, Vaduganathan, Muthiah, Verma, Subodh, Zieroth, Shelley, and Butler, Javed

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results